A Randomized, Double-blind, Double-dummy, Placebo-controlled, 3-period Crossover Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Orally Inhaled Indacaterol Administered Via the EPIC Test Fixture and the Concept1 Device in Adult Patients With Persistent Asthma

Trial Profile

A Randomized, Double-blind, Double-dummy, Placebo-controlled, 3-period Crossover Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Orally Inhaled Indacaterol Administered Via the EPIC Test Fixture and the Concept1 Device in Adult Patients With Persistent Asthma

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Indacaterol (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 11 Jul 2013 Planned End Date changed from 1 Oct 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 11 Jul 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 23 May 2013 New source identified and integrated (European Clinical Trials Database; EudraCT2011-001824-39).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top